Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Company Overview

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Key Stats

• Today's Range: $2.13 to $2.29
• 50-Day Range: $1.62 to $2.35
• 52-Week Range: $1.33 to $2.53
• Volume: 369,546 shs
• Average Volume: 994,381 shs
• Market Capitalization: $287.83 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.40
• Consensus Rating: Buy

Inhibikase Therapeutics Stock Analysis - MarketRank™

Inhibikase Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 209th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Inhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Inhibikase Therapeutics has a consensus price target of $5.40, representing about 147.7% upside from its current price of $2.18.

Amount of Analyst Coverage

Inhibikase Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($0.42) to ($0.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Inhibikase Therapeutics is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Inhibikase Therapeutics is -5.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Inhibikase Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.89% of the float of Inhibikase Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Inhibikase Therapeutics has a short interest ratio ("days to cover") of 16.94, which indicates bearish sentiment.

Change versus previous month

Short interest in Inhibikase Therapeutics has recently decreased by 5.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Inhibikase Therapeutics does not currently pay a dividend.

Dividend Growth

Inhibikase Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.23

News Sentiment

Inhibikase Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Inhibikase Therapeutics this week, compared to 2 articles on an average week.

Search Interest

7 people have searched for IKT on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.10% of the stock of Inhibikase Therapeutics is held by insiders.

Percentage Held by Institutions

3.81% of the stock of Inhibikase Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 8/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:IKT
• Previous Symbol: NYSE:IKT
• CIK: 1750149
• Web: N/A
• Phone: (678) 392-3419
• Fax: N/A
• Employees: 6
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Inhibikase Therapeutics: $5.40
• High Price Target: $8.00
• Low Price Target: $4.00
• Potential Upside/Downside: +147.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.26 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -41.31%
• Return on Assets: -38.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 30.14
• Quick Ratio: 30.14

Sales & Book Value

• Annual Sales: $260 thousand
• Price / Sales: 1,107.02
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.30 per share
• Price / Book: 0.95

Miscellaneous

• Outstanding Shares: 132,030,000
• Free Float: 122,659,000
• Market Cap: $287.83 million
• Optionable: N/A
• Beta: 0.94